Piper Sandler analyst Matt O'Brien reiterated an Overweight rating for Boston Scientific after the company reported preliminary Q4 results which fell short of consensus, saying the weakness was largely concentrated in CRM and a little in EP. While the light quarter is certainly disappointing, O'Brien tells investors in a research note that he continues to believe the fundamentals here remain strong and see a number of new product catalysts contributing in the coming quarters. Overall, he adds that despite the weakness, he remains positively inclined on the name as it is tough to bet against an accelerating growth story in large cap medtech.